Ignite Creation Date:
2024-05-06 @ 5:58 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05495724
Status:
RECRUITING
Last Update Posted:
2022-08-10
First Post:
2022-08-09
Brief Title:
Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Sponsor:
Tianjin Medical University Second Hospital
Organization:
Tianjin Medical University Second Hospital
Organization Data
Organization:
Tianjin Medical University Second Hospital
Class:
OTHER
Study ID:
TRUCE-04
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Tianjin Medical University Second Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None